文献速递淋巴瘤

利妥昔单抗嵌合抗CD20单克隆抗体治疗复发惰性淋巴瘤:半数患者对四剂治疗方案有应答

Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
PubMed 文献 · J Clin Oncol · 2023-01-01

这项多机构试验纳入31个中心的166例复发低级别或滤泡性淋巴瘤患者,每周静脉给予IDEC-C2B8 375 mg/m2共4次。意向治疗组48%有应答,中位随访11.8个月时应答者预计中位至进展时间13.0个月。多数不良事件发生于首次输注且为1或2级,仅12%患者出现3级、3%出现4级毒性。

要点

  • 复发惰性淋巴瘤患者接受IDEC-C2B8 375 mg/m2每周静脉给药共4次,意向治疗组应答率为48%。
  • 不良反应多为首次输注时的1或2级发热和寒战,3级毒性12%、4级毒性3%。
  • 仅1例患者检出人抗嵌合抗体。

核心结论

  • IDEC-C2B8的应答率为48%,与单药细胞毒化疗结果相当,毒性轻微。
  • 需要注意抗体输注速度,并根据毒性进行滴定。
  • 需要进一步研究该药物,包括与标准化疗联合使用。

研究设计与样本

  • 多机构试验,纳入31个中心的166例复发低级别或滤泡性淋巴瘤患者。
  • 门诊治疗,IDEC-C2B8 375 mg/m2静脉给药,每周1次,共4次。

主要发现

  • 意向治疗组166例中48%有应答。
  • 中位随访时间11.8个月,应答者预计中位至进展时间为13.0个月。
  • 血清抗体水平在第四次输注后比第一次输注后维持更久,且在应答者和肿瘤负荷较低的患者中更高。
  • 多数不良事件发生于首次输注且为1或2级,发热和寒战最常见。
  • 仅12%患者出现3级毒性,3%出现4级毒性;仅1例患者检出人抗嵌合抗体。

临床怎么用

  • 作者指出需要注意抗体输注速度,并根据毒性进行滴定。
  • 作者认为需要进一步研究该药物,包括与标准化疗联合使用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies. PATIENTS AND METHODS: This was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8. Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 intravenously weekly for four doses. RESULTS: From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13.0 months. Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden. The majority of adverse events occurred during the first infusion and were grade 1 or 2; fever and chills were the most common events. Only 12% of patients had grade 3 and 3% grade 4 toxicities. A human antichimeric antibody was detected in only one patient. CONCLUSION: The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy. Toxicity was mild. Attention needs to be paid to the rate of antibody infusion, with titration according to toxicity. Further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol. 2023. PMID: 36603541. doi:10.1200/JCO.22.02403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。